[go: up one dir, main page]

MX2018000897A - Celulas madre hematopoyeticas que expresan pd-l1 y usos. - Google Patents

Celulas madre hematopoyeticas que expresan pd-l1 y usos.

Info

Publication number
MX2018000897A
MX2018000897A MX2018000897A MX2018000897A MX2018000897A MX 2018000897 A MX2018000897 A MX 2018000897A MX 2018000897 A MX2018000897 A MX 2018000897A MX 2018000897 A MX2018000897 A MX 2018000897A MX 2018000897 A MX2018000897 A MX 2018000897A
Authority
MX
Mexico
Prior art keywords
hscs
stem cells
hematopoietic stem
pge2
modified
Prior art date
Application number
MX2018000897A
Other languages
English (en)
Inventor
Florina Paolo
Original Assignee
The Children´S Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children´S Medical Center Corp filed Critical The Children´S Medical Center Corp
Publication of MX2018000897A publication Critical patent/MX2018000897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las modalidades descritas aquí proporcionan células madre hematopoyéticas (HSCs) modificadas genéticamente, HSCs estimuladas artificialmente con prostaglandina E2 (PGE2), composiciones que comprenden estas HSCs, métodos para utilizar estas HSCs modificadas para tratar enfermedades y trastornos autoinmunes y para suprimir el sistema inmune. En particular, las HSCs modificadas genéticamente o HSCs estimuladas con PGE2 expresan el marcador de superficie, el ligando 1 de muerte celular programada-1 (PD-L1).
MX2018000897A 2015-07-21 2016-07-20 Celulas madre hematopoyeticas que expresan pd-l1 y usos. MX2018000897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562194969P 2015-07-21 2015-07-21
PCT/US2016/043053 WO2017015320A1 (en) 2015-07-21 2016-07-20 Pd-l1 expressing hematopoietic stem cells and uses

Publications (1)

Publication Number Publication Date
MX2018000897A true MX2018000897A (es) 2018-11-09

Family

ID=57835220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000897A MX2018000897A (es) 2015-07-21 2016-07-20 Celulas madre hematopoyeticas que expresan pd-l1 y usos.

Country Status (14)

Country Link
US (5) US20180214487A1 (es)
EP (1) EP3324982A4 (es)
JP (1) JP2018520688A (es)
KR (1) KR20180033537A (es)
CN (1) CN108135935A (es)
AU (1) AU2016296741A1 (es)
BR (1) BR112018001232A2 (es)
CA (1) CA2993201A1 (es)
HK (1) HK1249029A1 (es)
IL (1) IL257046A (es)
MX (1) MX2018000897A (es)
RU (1) RU2018106515A (es)
WO (1) WO2017015320A1 (es)
ZA (1) ZA201800798B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2760994T (pt) * 2011-09-30 2017-08-24 Bluebird Bio Inc Compostos para melhor transdução viral
EP2807250B1 (en) * 2011-11-23 2020-01-08 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
CA2974903A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
CN110520534A (zh) * 2016-11-09 2019-11-29 恩根尼公司 程序性死亡配体1的肠表达
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
EP3773742A4 (en) * 2018-04-06 2022-03-16 North Carolina State University CELL SET-MEDIATED CHECKPOINT INHIBITOR DELIVERY FOR CANCER IMMUNOTHERAPY
WO2020077037A1 (en) * 2018-10-10 2020-04-16 North Carolina State University Pd-l1 presenting platelets reverse new-onset type 1 diabetes
US11697799B2 (en) * 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN110734895A (zh) * 2019-11-06 2020-01-31 新乡学院 带有荧光标记的pd-l1膜表面表达细胞模型及其应用
US20230112857A1 (en) * 2020-01-10 2023-04-13 Modernatx, Inc. Methods of making tolerogenic dendritic cells
US20240024361A1 (en) * 2020-06-26 2024-01-25 The Children's Medical Center Corporation Methods and compositions for treating multiple sclerosis
CN113413464A (zh) * 2021-08-09 2021-09-21 中国人民解放军海军军医大学第一附属医院 抗pd-l1抗体在急性呼吸窘迫综合征治疗药物中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US6822112B1 (en) 1999-08-13 2004-11-23 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivatives
PT1132086E (pt) 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20060292618A1 (en) 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US20030194803A1 (en) 2002-04-12 2003-10-16 Mellor Andrew L. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
WO2003105887A1 (en) 2002-06-17 2003-12-24 Wyeth Inhibition of t cell activation by butyrophilin 4 or b7-l1
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
US7951592B2 (en) 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
CA2572467A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
EP1942739B1 (en) * 2005-10-18 2010-12-08 National Jewish Health Conditionally immortalized long-term adult stem cells and methods of making and using such cells
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
ZA200808123B (en) 2006-03-24 2010-03-31 Childrens Medical Center Method to modulate hematopoietic stem cell growth
RU2480213C2 (ru) 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Способ стимуляции регенерации тканей
EP2314300B1 (en) 2006-11-03 2013-10-09 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP3878949B1 (en) 2007-04-07 2025-06-04 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
CN101072380B (zh) 2007-06-08 2010-12-08 华为技术有限公司 内容下发方法及系统、网络设备、移动数据业务管理平台
EP2578677A1 (en) 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009086425A1 (en) 2007-12-28 2009-07-09 Fate Therapeutics, Inc. Methods for reprogramming cells to a pluripotent state and therapeutic applications related thereto
SG10201808863UA (en) 2008-03-17 2018-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US9101726B2 (en) 2008-04-07 2015-08-11 The Board Of Trustees Of The University Of Illinois Stem cell immune modulation methods of use and apparatus
US20110206781A1 (en) 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
PT3031907T (pt) 2008-11-06 2021-01-28 Univ Indiana Res & Tech Corp Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP2373784B1 (en) 2008-12-17 2017-10-25 The Scripps Research Institute Generation and maintenance of stem cells
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20120207744A1 (en) 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
WO2011031875A2 (en) 2009-09-11 2011-03-17 Fate Therapeutics, Inc. Cell-based compositions and uses thereof
CN102741394B (zh) 2009-10-16 2016-05-04 斯克里普斯研究所 多能细胞的诱导
CA2780572A1 (en) * 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modulated programmed death ligand-1
ES2727787T3 (es) 2009-11-15 2019-10-18 Univ Indiana Res & Tech Corp Métodos para mejorar el suministro y el injerto de células madre incluida la identificación de receptores específicos de prostaglandina E2
US20120263692A1 (en) * 2009-11-16 2012-10-18 Bertone Alicia L Engineered Xenogeneic Cells for Repair of Biological Tissue
CN102188446A (zh) * 2010-03-11 2011-09-21 中国医学科学院肿瘤研究所 人成体干细胞在治疗恶性实体瘤中的用途
AU2011237630B2 (en) 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
BR112013003366A2 (pt) 2010-08-12 2020-08-04 Fate Therapeutics, Inc. terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras
WO2012065027A2 (en) 2010-11-11 2012-05-18 University Of Miami Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
EP2807250B1 (en) 2011-11-23 2020-01-08 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
CA2857640C (en) 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
WO2014113439A1 (en) 2013-01-15 2014-07-24 Ohio State Innovation Foundation Methods for mobilizing hematopoietic stem cells
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
ES2966757T3 (es) 2014-03-04 2024-04-24 Fate Therapeutics Inc Métodos de reprogramación mejorados y plataformas de cultivo celular
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
CA2965347C (en) 2014-10-27 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
US20180291374A1 (en) 2014-11-12 2018-10-11 The General Hospital Corporation INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN107429230B (zh) 2015-01-26 2021-11-12 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US11186824B2 (en) 2015-03-11 2021-11-30 Cellectis Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
WO2016161196A1 (en) 2015-04-03 2016-10-06 Mirna Therapeutics, Inc. Microrna-34 immunotherapy
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
KR20250145703A (ko) 2015-09-02 2025-10-13 알닐람 파마슈티칼스 인코포레이티드 프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017100587A1 (en) 2015-12-09 2017-06-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
IL303077B2 (en) 2016-03-14 2025-06-01 Hoffmann La Roche Oligonucleotides for reduction of pd-l1 expression
CN110023490B (zh) 2016-10-19 2024-08-09 塞勒克提斯公司 用于改善的免疫细胞疗法的靶向基因插入

Also Published As

Publication number Publication date
AU2016296741A1 (en) 2018-02-22
US20200085878A1 (en) 2020-03-19
EP3324982A4 (en) 2019-01-09
IL257046A (en) 2018-03-29
WO2017015320A1 (en) 2017-01-26
HK1249029A1 (zh) 2018-10-26
KR20180033537A (ko) 2018-04-03
ZA201800798B (en) 2020-05-27
US20230321150A1 (en) 2023-10-12
US20200129559A1 (en) 2020-04-30
CN108135935A (zh) 2018-06-08
US10751373B2 (en) 2020-08-25
BR112018001232A2 (pt) 2018-09-25
US20190099450A1 (en) 2019-04-04
RU2018106515A (ru) 2019-08-21
RU2018106515A3 (es) 2019-12-09
US11642378B2 (en) 2023-05-09
CA2993201A1 (en) 2017-01-26
US20180214487A1 (en) 2018-08-02
US10517899B2 (en) 2019-12-31
EP3324982A1 (en) 2018-05-30
JP2018520688A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
MX2018000897A (es) Celulas madre hematopoyeticas que expresan pd-l1 y usos.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2019007020A (es) Anticuerpos il-11.
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
MX2021006786A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2017004691A (es) Bloqueo de cd73.
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
PH12017500803A1 (en) Anti-pd-1 antibodies
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
WO2016012544A3 (en) Enhanced reprogramming to ips cells
NZ769992A (en) Non-human animals having a humanized cluster of differentiation 47 gene
PH12017501875B1 (en) Compositions for modulating c9orf72 expression
SG10201806108TA (en) Binding proteins and methods of use thereof
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
PH12018500379B1 (en) Biopharmaceutical compositions
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
MX2016016903A (es) Animales no humanos que tienen un gen de muerte celular programada 1 humanizado.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX377300B (es) Terapia con células madre en patologías endometriales.
MX2018011534A (es) Metodos para transfectar plantas y para reducir eventos de integracion aleatoria.